CTOs on the Move

Ceregene

www.ceregene.com

 
Ceregene is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ceregene.com
  • 9381 Judicial Dr Ste 130
    San Diego, CA USA 92121
  • Phone: 858.458.8800

Executives

Name Title Contact Details

Similar Companies

BioTime

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.

Novagen

Novagen is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reaction Biology

Reaction Biology provides scientists worldwide with a trusted research partner supporting all phases of preclinical drug discovery from target validation through hit identification, hit to lead and lead optimization. Our portfolio covers most of your needs in drug discovery – over 1,000 biochemical targets, hundreds of cell-based assays, an extensive array of in vivo oncology models, along with custom assay development and protein production. Our team of Ph.D. scientists will provide you with collaborative support, quality data, and excellent communication, for a superior research result.

Piedmont Medical Laboratory

Piedmont Medical Laboratory is a Winchester, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mesoblast

Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.